Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Decision reversed: Medicare will not pay for OPT in occult wet AMD
Washington, DC-Citing concerns about safety and long-term benefits, the U.S. Centers for Medicare and Medicaid Services (CMS) has reversed its October 2001 decision to reimburse patients who receive ocular photodynamic therapy (PCT)
Related Videos
Related Content
